![The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck - International Journal of Radiation Oncology, Biology, Physics The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck - International Journal of Radiation Oncology, Biology, Physics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/92bdc805-aa8f-4050-8080-ca1f29daef5d/gr1.jpg)
The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck - International Journal of Radiation Oncology, Biology, Physics
![Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021 - Kidney International Reports Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021 - Kidney International Reports](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3c9adf07-e07e-447f-b08f-2e6d23151387/gr1_lrg.jpg)
Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021 - Kidney International Reports
![Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) - The Lancet Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d314687b-81bc-4d52-9ffc-6be0db0ff818/gr1.jpg)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) - The Lancet
![Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS - Annals of Oncology Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/43ca7cd4-144b-4115-94a6-5ef72c239b0e/gr1_lrg.jpg)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS - Annals of Oncology
アルコール除菌スプレー ドクタークリーン Dr.CLEAN+ 除菌・ウイルス除去スプレー 本体 500mL 16本/ケース エステー 業務用消耗品通販.com PayPayモール店 - 通販 - PayPayモール
![Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study | Journal of NeuroEngineering and Rehabilitation | Full Text Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study | Journal of NeuroEngineering and Rehabilitation | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12984-020-00771-6/MediaObjects/12984_2020_771_Fig4_HTML.png)
Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study | Journal of NeuroEngineering and Rehabilitation | Full Text
![Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2018/jco.2018.36.issue-17/jco.2017.77.6385/20180524/images/large/jco.2017.77.6385t6.jpeg)